Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
Patent Information
- Application Number
- MYPI1998002711
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 1998-03-27
- Filing Date
- 1998-06-17
- Publication Date
- 1998-12-18
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for non-insulin dependent diabetes mellitus (NIDDM) or Type II diabetes often require high doses of individual antihyperglycaemic agents, which may not provide optimal glycaemic control and can have adverse effects.
A combination of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (I)) with metformin or metformin hydrochloride, formulated in various pharmaceutical compositions, is administered to enhance glycaemic control with a synergistic effect, reducing the need for high doses of individual agents.
The combination provides effective glycaemic control with no observed adverse effects, improving indices like fasting plasma glucose, glycosylated haemoglobin, advanced glycosylation end products, leptin, and serum lipids, offering a more efficient treatment for Type II diabetes and associated conditions.
Abstract
Description
USE OF 5-[4-[2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY]BENZYL]THIAZOLIDfNE-2,4-DIONE AND METFORMIN FOR THE TREATMENT OF DIABETES MELLITUSThis invention relates to the treatment of diabetes mellitus, especially non-insulin dependent diabetes (NlDDM) or Type II diabetes and conditions associated with diabetes mellitus. Type Π diabetes and conditions associated with diabetes mellitus.Biguanide antihyperglycaemic agents are commonly used in the treatment of NIDDM (or Type II diabetes). 1,1- Dimethylbiguanidine (or Metformin) is an example of a biguanides antihyperglycaemic agent.European Patent Application, Publication Number 0,306228 relates to certain" thiazolidinedione derivatives disclosed as having antihyperglycaemic and hypolipidaemic activity. One particular thiazolidinedione disclosed in EP 0306228 is 54-[2-methyl-N-(2-pyridyi)amino)elhoxy]ben2yI]thiazoUdine-2,4-dione . (hereinafter 'Compound (I)*). W094 / 05659 discloses certain salts of Compound (I) including the maleate salt at example 1 thereof.Compound (I) is an example of a class of anti-hyperglycaemic agents known as lITTailiTi sensitiseis'. In particular Compound (T) is a thiazolidinedione sensitiser.European Patent Applications, Publication Numbers: 0008203, 0139421, . 0032128,0428312,0489663,0155845,0257781,0208420,0177353,0319189, 0332331,0332332, 0528734,0508740; International Patent Application, Publication Numbers 92 / 18501,93 / 02079, 93 / 22445 and United Stales Patent Numbers 5104888 and 5478852, also disclose certain thiazolidinedione insulin sensitisers.Another series of compounds generally recognised as having insulin sensitiser activity are those typified by the compounds disclosed in International Patent Applications, Publication Numbers W093 / 21166 and W094 / 01420. These compounds are herein referred to as 'acyclic insulin sensitisers'; Other examples of acyclic sensitisers are those disclosed in United States Patent Number 5232945 and International Patent Applications, Publication Numbers WO92 / 03425 and W091 / 19702.Examples of other insulin sensitisers are those disclosed in European Patent Application, Publication Number 0533933, Japanese Patent Application Publication I Number 05271204 and United States Patent Number 5264451.He above mentioned publications are incorporated herein by reference. It is now surprisingly indicated that Compoimd (I) in combination with a biguanide antihyperglycaemic agent provides a particularly beneficial effect on glycaemic control with no observed adverse effects, such combination is therefore particularly useful for the treatment of diabetes mellitus, especially Type Π diabetes and conditions associated with diabetes mellitus.Accordingly the present invention provides a combination which comprises from 2 to 12 mg of 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (I)) or a pharmaceutically acceptable fonn thereof, and up to 3000 mg of metformin or metformin hydrochloride.In one aspect, the combination comprises from 2 to 4, 4 to 8 or 8 to 12 mg of Compound (I) or a pharmaceutically acceptable fonn thereof.Typically, the combination comprises from 2 to 4 mg of Compound (I) or a pharmaceutically acceptable fonn thereof.Typically, the combination comprises from 4 to 8 mg of Compound (I) or a pharmaceutically acceptable form thereof.Typically, the combination comprises from 8 to 12 mg of Compound (I) or a pharmaceutically acceptable form thereof.Preferably, the combination comprises 2 mg of Compound (I) or a pharmaceutically acceptable fonn thereof.Preferably, the combination comprises 4 mg of Compound (I) or a pharmaceutically acceptable form thereof.Preferably, the combination comprises 8 mg of Compound (I) or a pharmaceutically acceptable form thereof.Preferably, the combination of the present invention comprises 500 mg or 850 mg of metformin or metformin hydrochloride.Preferably, the combination is one wherein Compound (I) or a pharmaceutically acceptable form thereof and up to 3000 mg of metformin or metformin hydrochloride are formulated as a single pharmaceutical composition.Preferably, the combination is one wherein Compound (I) or a pharmaceutically acceptable form thereof and up to 3000 mg of metformin or metformin hydrochloride are formulated as separate pharmaceutical compositions.The present invention further provides a pharmaceutical composition comprising from 2 to 12 mg of 5-[4-[2-(N-methyl-N-(2-pyndyl)amino)eth oxy] benzyl] thiazo Ii dine-2,4 -dione (Compound (I)) or apharmaceutically acceptable fonn thereof, up to 3000 mg of metformin or metformin hydrochloride and a pharmaceutically acceptable earner therefor.The method of administration of Compound (I) or a pharmaceutically acceptable form thereof, and metformin or metformin hydrochloride or the sequential administration thereof.Co-administration includes administration of a formulation which includes both Compound (I) or a pharmaceutically acceptable from thereof, and metformin or metformin hydrochloride or the essentially simultaneous administration of separate formulations of each agent.In another aspect the present invention provides use of from 2 to 12 mg of 5-[4-[2-(N-methyl-N-(2-pyiidyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione (Compound (I)) or a pharmaceutically acceptable fonn thereof and up to 3000 mg of metformin or metformin hydrochloride in the manufacture of a medicament for use in the treatment of diabetes mellitus or a condition associated with diabetes mellitus. J Further, the present invention provides use of from 2 to 12 mg of 5-[4-[2-(N- methyl-N-(2-pyi'idyl)amino)ethoxy]benzyl]thiazolidine-2.4-dione (Compound (I)) or a pharmaceutically acceptable fonn thereof in the manufacture of a medicament for use with up to 3000 mg of metformin or metformin hydrochloride in the treatment of diabetes mellitus or a condition associated with diabetes mellitus.Still further the present invention provides use of up to 3000 mg of metformin or metformin hydrochloride in the manufacture of a medicament for use with from 2 to 12 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (I)) or a pharmaceutically acceptable form thereof in the treatment of diabetes mellitus or a condition associated with diabetes mellitus.It will be understood that Compound (I) is administered in a pharmaceutically acceptable fonn, including pharmaceutically acceptable derivatives such as pharmaceutically acceptable salts, esters and solvates thereof, as appropriate. It will be understood that all pharmaceutically acceptable forms of the active agent per se are encompassed by this invention, j Suitable pharmaceutically acceptable forms of Compound (I) include those described in EP 0306228 and W094 / 05659, especially pharmaceutically acceptable salted forms. A preferred pharmaceutically acceptable salt is a maleate.Suitable pharmaceutically acceptable forms of Compound (I) include those described in EP 0306228 and W094 / 05659, in particular hydrates.Compound (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, may be prepared using known methods, for example those disclosed in EP 0306228 and W094 / 05659. The disclosures of EP 0306228 and W094 / 05659 are incorporated herein by reference.Compound (I) may exist in one of several tautomeric forms, all of which are encompassed by the term Compound (I) as individual tautomeric forms or as mixtures thereof. Compound (I) contains a cbiral carbon atom, and hence can exist in up to two stereoiosmeric forms, the term Compound (I) encompasses all of these isomeric forms whether as individual isomers or as mixtures of isomers, including racemates.Compound (I), pharmaceutically acceptable forms thereof, metformin and metformin hydrochloride are prepared according to known methods, such methods are found or are referred to in standard reference texts, such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra PhaiTnacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition on page 341 and pages cited therein) or as described in the above-mentioned publications.When used herein the term 'conditions associated with diabetes' includes those conditions associated with the pre-diabetic state, conditions associated with diabetes mellitus itself and complications associated with diabetes mellitus.When used herein the term 'conditions associated with the pre-diabetic state' includes conditions such as ϊη·π»Κη resistance, including hereditary insulin resistance, impaired glucose tolerance and hyperinsulinaemia.Conditions associated with diabetes mellitus itself include hyperglycaeinia, ΐη<ηιΙΐη resistance, including acquired jnsnKn resistance and obesity. Further conditions associated with diabetes mellitus itself include hypertension and cardiovascular disease, especially atherosclerosis and conditions associated with insulin resistance. Conditions associated with insulin resistance include polycystic ovarian syndrome and steroid induced insulin resistance and gestational diabetes.Complications associated with diabetes mellitus' includes renal disease, especially renal disease associated with Type II diabetes,neuropathy and retinopathy.Renal diseases associated with Type Π diabetes include nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renai disease.As used herein the term 'pharmaceutically acceptable' embraces both human and veterinary use: for example the term 'pharmaceutically acceptable' embraces a veterinarily acceptable compound.For the avoidance of doubt, when reference is made herein to scalar amounts, including mg amounts, of Compound (I) in a pharmaceutically acceptable fonn, the scalar amount referred to is made in respect of Compound (I) per se: For example 2 mg ofCompound (I) in the form of the maleate salt is that amount of maleate salt which contains 2 mg of Compound (I).Diabetes mellitus is preferably Type II diabetes.The particularly beneficial effect on glycaemic control provided by the treatment of the invention is indicated to be a synergistic effectrelative to the control expected for the sum of the effects of the individual active agents.Glycaemic control may be characterised using conventional methods, for example by measurement of a typically used index of glycaemic control such as fasting plasma glucose or glycosylated haemoglobin (Hb Ale). Such indices are determined using standard methodology, for example those described in: Tuescher A, Richterich, P., Schweiz. med. Wschr. 101 (1971), 345 and 390 and Frank P., J "Monitoring the Diabetic Patent with GlycosoIated Hemoglobin Measurements', Clinical Products 1988.In a preferred aspect, the dosage level of each of the active agents when used in accordance with the treatment of the invention will be less than would have been required from a. purely additive effect upon glycaemic control.There is also an indication that the treatment of the invention will effect an improvement, relative to the individual agents, in the levels of advanced glycosylation end products (AGEs), leptin and serum lipids including total cholesterol, HDL-cholesterol, LDL-cholesterol including improvements in the ratios thereof in particular an improvement in serum lipids including total cholesterol, HDL-cholesteroL, LDL-cholesterol including improvements in the ratios thereofThe active medicaments are preferably administered in pharmaceutical composition form. As indicated above, such compositions can include both medicaments or one only of the medicaments.Accordingly, in one aspect of the invention there is provided a pharmaceutical composition comprising from 2 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (I)) or a pharmaceutically acceptable form thereof, up to 3000 mg of metformin or metformin hydrochloride and a pharmaceutically acceptable carrier thereof.Such compositions may be prepared by admixing from 2 to 8 mg of Compound (I) or a pharmaceutically acceptable form thereof, metformin or metformin hydrochloride and a pharmaceutically acceptable carrier therefor.Usually the compositions are adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration, sublingual or transdermal administration.The compositions may be in the form of tablets, capsules, powders, granules, I lozenges, suppositories, reconstitutable powders, orliquid preparations, such as oral or sterile parenteral solutions or suspensions.In order to obtain consistency of administration it is preferred that a ( composition of the invention is in the form of a unit dose.Unit dose presentation forms for oral administration may be tablets and I capsules and may contain conventional excipients such asbinding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine;tabletting lubricants, for example magnesium stearale; disintegrants, for example starch, polyvinylpyrrolidone, sodium starchglycollate or macrocrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lanryl sulphate.The compositions are preferably in a unit dosage fonn in an amount appropriate for the relevant daily dosage.Suitable unit dosages of the Compound of formula (I) comprise 2, 3, 4, 5, 6,7 or 8 mg of Compound (I).The composition of the invention may be administered from 1 to 6 times a day, but most preferably 1 or 2 times per day.Particular dosages of Compound (I) are are 2mg / day, 4mg / day, including 2mg twice per day, and 8 mg / day, including 4mg twice perday.Suitable dosages of metformin or metformin hydrochloride include up to 3000mg per day, in unit doses of 500mg (for example two orthree times per day) or 850mg (for example two times per day), one example of a dosage for metformin is 500mg once building to five times per day.Thus, one example of administration of the combination of the present invention is 4 or 8mg of Compound (I) (at 2mg twice per day or 4mg twice per day respectively) and IOOOmg or 2500mg of metformin (at 500mg twice per day or 500mg five times per day respectively).The solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repealed blending operationsmay be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, inparticular with an enteric coaling.Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearale gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same maimer, except that the Compound (I)s suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound-Compositions may contain from 0.1% to 99% by weight, preferably from ) 10-60% by weight, of the active material, depending uponthe method of administration.Compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use.The compositions are formulated according to conventional methods, such as I those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) and Harry's Cosmeticology (Leonard Hill Books). D A range of 2 to 4mg includes a range of 2.1 to 4,22 to 4, 23 to 4, 2.4 to 4,2-5 to 4,2.6 to 4,2.7 to 4,2.8 to 4, 2.9 to 4 or 3 to 4mg.A range of 4 to 8mg includes a r2nge of 4.1 to 8, 4.2 to 8, 4.3 to 8,4.4 to 8, 4.5 to 8, 4.6 to 8,4.7 to 8,4.8 to 8, 4.9 to 8, 5 to 8, 6 to 8 or 7 to 8mg.A range of 8 to 12 mg includes a range of 8.1 to 12, 8.2 to 12, 83 to 12, 8.4 3 to 12, 8.5 to 12, 8.6 to 12, 8.7 to 12, 8.8 to 12, 8.9 to 12, 9 to 12,10 to 12 or 11 to 12mg.No adverse toxicological effects have been established for the compositions or methods of the invention in the abovementioned dosage ranges. *The following example illustrates the invention but does not limit it in any0 wyExampleThis study evaluated the pharmacokinetics (PK) of Compound (I) and metformin (M) administered alone and in combination. Sbcleen male volunteers, aged 22 to 55 years, received oral Compound (I) (2 mg Q12h), M (500 mg Q12h), or the combination, each for 4 days. Plasma collected on day 4 of each regimen was assayed for Compound (I) and M concentrations. Oral doses of Compound (I) and M were safe and well tolerated alone or in combination. There were no episodes of hypoglycaemia and co-administration did not' result in an increase in blood lactic acid concentration.Combo = Compound (I) + M coadministrationCoadministration of Compound (I) and M did not affect the steady-state pharmacokinetics I (AUC(0-12), Cmax5Tmax, or Tl / 2) of either drug. BecauseMplasmaconcentrations were unaffected, coadministration or Compound (I) will not accentuate the concentration-dependent toxicities of M-COMPOUND (I) COMPOSmONS A Concentrate PreparationApproximately two thirds of the lactose monohydrate is passed through a suitable screen and blended with the milled maleate salt of Compound (I). Sodium starch glycollate, hydoxypropyl methylcellulose, microcrystalline cellulose and the remaining lactose are passed through a suitable screen and added to the mixture. Blending is then continued. The resulting mixture is then wet granulated with purified water. The wet granules are then screened, dried on a fluid bed drier and the dried granules are passed through a further screen and finally homogenised.% COMPOSITION OF GRANULAR CONCENTRATEB Formulation of the concentrate into tablets.The granules from above are placed into a tumble blender. Approximately two thirds of the lactose is screened and added to the blender. The microcrystalline cellulose, sodium starch glycollate, magnesium stearate and remaining lactose are screened and addedto the blender and the mixture blended together. The resulting mix is then compressed on a rotary tablet press to a target weight of 150mg for the 1,2 and 4mg tablets and to a target weight of 300mg for the Smg tablets.The tablet cores are then transferred to a tablet coating machine, pre-wanned with warm air (approximately 65 °C) and film coated until the tablet weight has increased by 2.0% to 3.5%.
Claims
CLAIMS 1. A pharmaceutical composition which comprises from 2 to 8 mg of 5-[4-[2-Nmethyl-(N-(2pyridyl)amino)ethoxy]benzyl]thia2olidine-2,4-dione (Compound (I)) or a pharmaceutically acceptable form thereof, up to 3000 mg of metformin or metformin hydrochloride and a pharmaceutically acceptable 5 earner therefor.
2. A composition according to claim 1, which comprises from 2 to 4 or 4 to 8 mg of Compound (I) or a pharmaceutically acceptable form thereof.
3. A composition according to claim 1 or claim 2, which comprises from 2 to4 mg of Compound (I) or a pharmaceutically acceptable form thereof. 10 4. A composition according to claim 1 or claim 2, which comprises from 4 to 8 mg of Compound (I) or a pharmaceutically acceptable form thereof.
5. A composition according to any one of claims 1 to 3, which comprises 2 mg of Compound (I) or a pharmaceutically acceptable form thereof.
6. A composition according to any one of claims 1 to 4, which comprises 4 mg 15 of Compound (I) or a pharmaceutically acceptable form thereof.
7. A composition according to any one of claims 1,2 and 4, which comprises 8 mg of Compound (1) or a pharmaceutically acceptable form thereof.
8. A composition according to any one of claims 1 to 7, which comprises 500 mg or 850 mg of metformin or metformin hydrochloride.
209. A composition according to any one of claims 1 to 8 which comprises the PI 98002711 maleate salt of Compound (I).
10. Use of from 2 to 8 mg of 5-[4-[2-N-methyl-(N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (1)) or a pharmaceutically acceptable form thereof and up to 3000 mg of metformin or 5 metformin hydrochloride in the manufacture of a medicament for use in the treatment of diabetes mellitus or a condition associated with diabetes mellitus.
11. Use according to claim 10, which comprises from 2 to 4 or 4 to 8 mg of Compound (I) or a pharmaceutically acceptable form thereof. 1012. Use according to claim 10 or claim 11, which comprises from 2 to 4 mg of Compound (I) or a pharmaceutically acceptable form thereof.
13. Use according to claim 10 or claim 11, which comprises from 4 to 8 mg of Compound (I) or a pharmaceutically acceptable form thereof.
14. Use according to any one of claims 10 to 12, which comprises 2 mg of15 Compound (I) or a pharmaceutically acceptable form thereof.
15. Use according to any one of claims 10 to 13, which comprises 4 mg of Compound (I) or a pharmaceutically acceptable form thereof.
16. Use according to any one of claims 10,11 or 13, which comprises 8 mg of Compound (I) or a pharmaceutically acceptable form thereof.
17. Use according to any one of claims 10 to 16, which comprises 500 mg or 850 mg of metformin or metformin hydrochloride. PI 98002711 20=18. Use according to any one of claims 10 to 17, which comprises the maleate salt of Compound (I).
19. A combination which comprises from 2 to 8 mg of 5-[4'[2-N-methyl-(N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (1)) or a pharmaceutically acceptable form thereof, and up to 3000 mg of metformin or metformin hydrochloride.
20. A combination according to claim 19, which comprises from 2 to 4 or 4 to 8 mg of Compound (I) or a pharmaceutically acceptable form thereof.
21. A combination according to claim 19 or claim 20, which comprises from 2 to 4 mg of Compound (I) or a pharmaceutically acceptable form thereof.
22. A combination according to claim 19 or claim 20, which comprises from 4 to 8 mg of Compound (I) ot a pharmaceutically acceptable form thereof.
23. A combination according to any one of claims 19 to 21, which comprises 2 mg of Compound (I) or a pharmaceutically acceptable form thereof.
24. A combination according to any one of claims 19 to 22, which comprises 4 mg of Compound (I) or a pharmaceutically acceptable form thereof.
25. A combination according to any one of claims 19,20 and 22, which comprises 8 mg of Compound (I) or a pharmaceutically acceptable form thereof.
26. A combination according to any one of claims 19 to 25, which comprises 500 mg or 850 mg of metformin or metformin hydrochloride.
